Director Acquires Shares

RNS Number : 6352U
OKYO Pharma Limited
30 March 2023
 

Director Acquires Shares

London and New York, NY, 30 March, 2023  - OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease ("DED") to address the significant unmet need in this multi-billion-dollar market, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 11,000 of the Company's ADSs on NASDAQ at a price of US$1.41 per ADS (which would be equivalent to the purchase of 715,000 ordinary shares of no par value ("Ordinary Shares") at a price of £0.0176 each).

1.

Details of PDMR / person closely associated

a)

Name

Gabriele Cerrone

2.

Reason for the notification

a)

Position / status

Chairman

b)

Initial notification /amendment

Initial notification

3.

Details of the issuer

a)

Name

OKYO Pharma Limited

b)

LEI

213800VVN5CB56Y15A05

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type  of transaction; (iii) each date; and (iv) each place where transactions have  been conducted

a)

Description of the financial instrument

ADSs representing 65 Ordinary Shares of no par value

b)

Identification code of the Financial Instrument

ISIN for OKYO Pharma Limited GG00BD3FV870

c)

Nature of the transaction

Market Purchase

d)

Price(s) and volume(s)

$1.41 - 11,000

 

f)

Date of the transaction

28 March 2023

g)

Place of the transaction

NASDAQ

 

Enquiries:

OKYO Pharma Limited

Gary S. Jacob, Chief Executive Officer

 

+44 (0)20 7495 2379

 

Investor Relations

Paul Spencer

+44 (0)20 7495 2379

 

 

 

Broker

 

Robert Emmet, Optiva Securities Limited

 

+44 (0)20 3981 4173

Notes for Editors:

About OKYO

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on NASDAQ and on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. For further information, please visit www.okyopharma.com .

 

About OK-101

OK-101 is a lipid conjugated chemerin peptide antagonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide (MAP) technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain; and is designed to combat washout through the inclusion of the lipid 'anchor' contained in the candidate drug molecule to enhance the residence time of OK-101 within the ocular environment.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSEDFSUEDSEFD
UK 100

Latest directors dealings